Drugs / R-2487
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06297213 | Jun 2026 → Aug 2028 expected | Sjogren syndrome | Rise Therapeutics LLC | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05961592 | Oct 2023 → Nov 2026 expected | rheumatoid arthritis | Rise Therapeutics LLC | Recruiting | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-02 | Rise Therapeutics LLC | Rise Therapeutics Completes Enrollment in Four-Week Dose Expansion Cohort for the R-2487 Rheumatoid Arthritis Clinical Trial risetherapeutics.com ↗ |
| 2025-09-23 | Rise Therapeutics LLC | Rise Therapeutics Secures New Funding to Advance First-in-Class R-2487 Oral Immune Biomodulator into Sjogren’s Disease Clinical Testing risetherapeutics.com ↗ |
| 2025-01-06 | Rise Therapeutics LLC | Dose Escalation Completed for Rise Therapeutics’ R-3750 and R-2487 Clinical Trials risetherapeutics.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R-2487 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05961592 ↗ |
| Modality | Other / unclassified | “orally taken probiotic (R-2487)” NCT06297213 ↗ |
| Route | Oral | “orally taken probiotic (R-2487)” NCT05961592 ↗ |